Brain Functional Magnetic Resonance Imaging Cue-reactivity Can Predict Baclofen Response in Alcohol Use Disorders

다국어 초록 (Multilingual Abstract)

Objective: Baclofen is a promising treatment for alcohol use disorders (AUD), although its clinical response in humans is mixed. The present study aimed at investigating the impact of baclofen treatment on cue-induced brain activation pattern and its relationship with relapse outcomes.
Methods: Twenty-three inpatients with AUD underwent a functional magnetic resonance imaging cue-reactivity task before beginning medication with baclofen and 2 weeks later. Twelve additional inpatients with AUD, who did not receive any anticraving medications, formed the control group. All subjects were prospectively followed up for 90 days post-discharge or until lapse to first alcohol use.
Results: Whole-brain linear mixed effects analysis revealed a significant group-by-time interaction with greater activation of the bilateral dorsolateral pre-frontal cortex and right anterior cingulate cortex (ACC) following baclofen treatment in comparison with the control group. Further, cox regression analysis revealed that increased activation of ACC and deactivation of insular cortex (IC) was associated with longer time to first alcohol use only in the baclofen treatment group but not in the control group.
Conclusion: This study provides preliminary evidence for the neural predictors of baclofen treatment response in AUD.
Baclofen treatment in AUD was associated with changes in cue-reactivity at critical brain regions within the incentive- salience network. Importantly, baclofen treatment-related specific activation of regions involved in cognitive control (ACC) and deactivation of regions involved in reward anticipation (IC) prolonged the time to first alcohol drink

참고문헌 (Reference)

1 Gilman JM, "Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol" 28 : 4583-4591, 2008

2 Holla B, "Visual image-induced craving for ethanol (VICE): development, validation, and a pilot fMRI study" 36 : 164-169, 2014

3 Monti PM, "Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving" 95 (95): S229-S236, 2000

4 Groefsema M, "The role of social stimuli content in neuroimaging studies investigating alcohol cue-reactivity" 58 : 123-128, 2016

5 Naqvi NH, "The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making" 214 : 435-450, 2010

6 Langosch JM, "The impact of acamprosate on cue reactivity in alcohol dependent individuals: a functional magnetic resonance imaging study" 32 : 661-665, 2012

7 Myrick H, "The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics" 30 : 365-372, 2010

8 Oldfield RC, "The assessment and analysis of handedness: the Edinburgh inventory" 9 : 97-113, 1971

9 World Health Organization, "The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines"

10 de Beaurepaire R, "Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients" 3 : 103-, 2012

11 Gilman JM, "Subjective and neural responses to intravenous alcohol in young adults with light and heavy drinking patterns" 37 : 467-477, 2012

12 Schneider F, "Subcortical correlates of craving in recently abstinent alcoholic patients" 158 : 1075-1083, 2001

13 Power JD, "Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion" 59 : 2142-2154, 2012

14 Menon V, "Saliency, switching, attention and control: a network model of insula function" 214 : 655-667, 2010

15 Brett M, "Region of interest analysis using the MarsBar toolbox for SPM 99" 16 (16): S497-, 2002

16 Flannery BA, "Psychometric properties of the Penn Alcohol Craving Scale" 23 : 1289-1295, 1999

17 Mann K, "Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging" 38 : 2754-2762, 2014

18 Zindel LR, "Pharmacotherapy of alcohol use disorders: seventy-five years of progress" 75 (75): 79-88, 2014

19 Ekhtiari H, "Neuroscience of drug craving for addiction medicine: From circuits to therapies" 223 : 115-141, 2016

20 Courtney KE, "Neural substrates of cue reactivity: association with treatment outcomes and relapse" 21 : 3-22, 2016

21 Soyka M, "Nalmefene for the treatment of alcohol dependence: a current update" 17 : 675-684, 2014

22 Friston KJ, "Movement-related effects in fMRI time-series" 35 : 346-355, 1996

23 Franklin TR, "Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study" 117 : 176-183, 2011

24 Benegal V, "India: alcohol and public health" 100 : 1051-1056, 2005

25 Williams ZM, "Human anterior cingulate neurons and the integration of monetary reward with motor responses" 7 : 1370-1375, 2004

26 Muller CA, "High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial" 25 : 1167-1177, 2015

27 World Health Organization, "Global status report on alcohol and health 2014" World Health Organization 2014

28 Schacht JP, "Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review" 18 : 121-133, 2013

29 Jasinska AJ, "Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies" 38 : 1-16, 2014

30 Cox RW, "FMRI clustering in AFNI: false-positive rates redux" 7 : 152-171, 2017

31 Lukas SE, "Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study" 78 : 176-185, 2013

32 Beraha EM, "Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial" 26 : 1950-1959, 2016

33 Garbutt JC, "Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial" 34 : 1849-1857, 2010

34 Spagnolo PA, "Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients" 38 : 3024-3032, 2014

35 Schacht JP, "Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics" 227 : 627-637, 2013

36 Leggio L, "Effectiveness and safety of baclofen in the treatment of alcohol dependent patients" 9 : 33-44, 2010

37 Addolorato G, "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study" 370 : 1915-1922, 2007

38 Myrick H, "Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people" 65 : 466-475, 2008

39 Beck A, "Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients" 69 : 842-852, 2012

40 Swift RM, "Drug therapy for alcohol dependence" 340 : 1482-1490, 1999

41 McLellan AT, "Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation" 284 : 1689-1695, 2000

42 Goldstein RZ, "Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex" 159 : 1642-1652, 2002

43 Addolorato G, "Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial" 46 : 312-317, 2011

44 Myrick H, "Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving" 29 : 393-402, 2004

45 Sjoerds Z, "Cue reactivity is associated with duration and severity of alcohol dependence: an FMRI study" 9 : e84560-, 2014

46 Shukla L, "Correlates of baclofen effectiveness in alcohol dependence" 37 : 370-373, 2015

47 Ameisen O, "Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician" 40 : 147-150, 2005

48 Kuhn S, "Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response" 33 : 1318-1326, 2011

49 Cruz HG, "Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system" 7 : 153-159, 2004

50 Addolorato G, "Baclofen: a new drug for the treatment of alcohol dependence" 60 : 1003-1008, 2006

51 Morley KC, "Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety" 49 : 654-660, 2014

52 Liu J, "Baclofen for alcohol withdrawal" (1) : 2011

53 Addolorato G, "Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study" 37 : 504-508, 2002

54 Ponizovsky AM, "Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up" 52 : 24-30, 2015

55 Nielsen FA, "Automatic anatomical labeling of Talairach coordinates and generation of volumes of interest via the BrainMap database" 16 (16): 1126-1128, 2002

56 Sullivan JT, "Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)" 84 : 1353-1357, 1989

57 Kareken DA, "Alcohol-related olfactory cues activate the nucleus accumbens and ventral tegmental area in high-risk drinkers: preliminary findings" 28 : 550-557, 2004

58 Braus DF, "Alcohol-associated stimuli activate the ventral striatum in abstinent alcoholics" 108 : 887-894, 2001

59 Gururaj G, "Alcohol related harm: implications for public health and policy in India"

60 Franklin TR, "Acute baclofen diminishes resting baseline blood flow to limbic structures: a perfusion fMRI study" 125 : 60-66, 2012

61 George MS, "Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol- specific cues" 58 : 345-352, 2001

62 Leggio L, "A human laboratory pilot study with baclofen in alcoholic individuals" 103 : 784-791, 2013